Clinical Trials Browser

Small Cell Lung Carcinoma

NCT07192926 2026-02-20

SARCO-CTI

Completed

131 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT06634199 2026-01-28

SIENNA

Recruiting

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06826677 2025-06-24

ARAL

Completed

71 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04667312 2023-10-02

CODAK

Completed

115 enrolled

Thoracic

Non-Small Cell Lung Cancer NSCLC

NCT04364776 2023-09-28

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Unknown

100 enrolled

Thoracic

Lung Neoplasms

NCT05933044 2023-09-05

RELEVANCE

Completed

662 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT04285866 2022-06-07

S-REAL

Completed

245 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04672759 2020-12-17

A Real-world Study of Durvalumab for Lung Cancer in China

Unknown

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Clinical Trials

ARSENAL

SARCO-CTI

SIENNA

ARAL

CODAK

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

RELEVANCE

Microbiome Immunotherapy Toxicity and Response Evaluation

S-REAL

A Real-world Study of Durvalumab for Lung Cancer in China